Plus Therapeutics Publishes Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma Patients with Median Overall Survival of 17 Months

Plus Therapeutics' Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma patients, with patients receiving >100 Gy achieving a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care. The data was published in a peer-reviewed manuscript in Nature Communications and supports the ongoing ReSPECT-GBM Phase 2 trial.

Glioblastoma (GBM), an aggressive and deadly form of brain cancer, has long been a challenge for medical professionals to treat effectively. However, recent developments in the field of targeted radiation therapy, specifically Plus Therapeutics' Rhenium (186Re) Obisbemeda, are offering new hope for patients.

Rhenium (186Re) Obisbemeda is a promising drug candidate designed for the treatment of recurrent GBM, leptomeningeal metastases (LM), and pediatric brain cancers (PBCs) such as ependymoma and high-grade glioma. Preclinical and clinical trials, including the ReSPECT-GBM and ReSPECT-LM studies, have shown that this innovative approach delivers up to 20 times the absorbed dose of radiation versus standard external beam radiation therapy (EBRT), effectively reducing tumors without significant toxicity [1].

In a preclinical trial of Rhenium (186Re) Obisbemeda for treating LM, researchers administered highly elevated doses of the drug with no maximum tolerable dose reached [1]. These results support the ongoing ReSPECT-GBM Phase 2 trial, which aims to evaluate the safety, response, and potential efficacy of Rhenium (186Re) Obisbemeda in treating recurrent GBM.

The novel approach behind Rhenium (186Re) Obisbemeda involves drug loading using a specially developed small molecule called BMEDA with the radioisotope, Rhenium-186, and carrying it into the interior of a nanoliposome where it is irreversibly trapped. Upon administration, Rhenium-186 emits beta energy that precisely targets rapidly dividing cancer cells, sparing the surrounding healthy cells and tissue, as well as gamma energy that allows for live imaging of the full treatment infusion [1].

Rhenium-186 emits beta energy with a short average tissue penetration length of approximately 2 mm, localizing the attack to the tumor. The nanoliposome carrier is also nontoxic, degrading naturally in the body. In the ReSPECT-GBM clinical trial, Rhenium (186Re) Obisbemeda was administered at a dose up to 15-20 times higher than EBRT, destroying cancer more effectively and prolonging survival with fewer side effects [1].

The potential benefits of Rhenium (186Re) Obisbemeda extend beyond its ability to effectively treat brain cancer. Its targeted delivery system spares healthy cells and tissue, reducing the risk of side effects commonly associated with traditional radiation therapy. Additionally, the live imaging capabilities of gamma energy allow medical professionals to monitor the treatment process in real-time, ensuring that the therapy is delivering the desired results.

In conclusion, Plus Therapeutics' Rhenium (186Re) Obisbemeda is a promising new development in the field of targeted radiation therapy for the treatment of glioblastoma and other brain cancers. With its innovative approach, targeted delivery system, and potential to improve patient outcomes and reduce side effects, this drug candidate has the potential to be a game-changer in the field of cancer treatment.

References:
[1] Plus Therapeutics. (2022). 186rnl. Retrieved January 26, 2023, from https://plustherapeutics.com/186rnl/